ペグフィルグラスチムバイオシミラーの世界市場レポート 2025年

ペグフィルグラスチムバイオシミラー市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR17.5％で34億4,000万米ドルに成長します。予測期間の成長は、がんの有病率の増加、人口の高齢化、承認数の増加、ターゲットとインセンティブに起因すると考えられます。予測期間における主な動向としては、規制が緩やかであることを利用して新しく改良されたバイオシミラーを開発すること、効果的で革新的な生物製剤を開発するために研究開発活動に広範な投資を行うこと、新薬開発の研究開発活動を拡大するために大手企業との戦略的パートナーシップの確立に注力すること、顧客基盤とその地域市場を拡大するためにM&A成長戦略に重点を置くようになること、収益と製品提供を改善するために好中球減少症治療のためのバイオシミラーの生産に重点を置くようになることなどが挙げられます。

バイオシミラーの開発促進を目的とした政府のイニシアチブは、ペグフィルグラスチムバイオシミラー市場の推進力になると予想されます。世界規模の政府は、費用対効果の高さからバイオシミラー開発を優先しています。米国食品医薬品局（FDA）が治療の選択肢を広げるために打ち出したバイオシミラー・アクション・プランや、オーストラリア政府がバイオシミラーに関する教育や活動を支援するために500万米ドルの助成金を拠出し、バイオシミラー啓発イニシアティブに取り組んでいることなどは、バイオシミラーの認知度向上と生産に向けた協調的な取り組みを浮き彫りにしています。こうした努力は、ペグフィルグラスチムバイオシミラー市場全体の成長に貢献しています。

がん罹患率の上昇は、今後数年間のペグフィルグラスチムバイオシミラー市場の成長を牽引すると予想されます。がんは、異常な細胞の無秩序な増殖と拡散を特徴とする様々な疾患を包含します。ペグフィルグラスチムバイオシミラーは、白血球の産生を促進することで、化学療法を受けるがん患者の感染リスクを軽減するという重要な役割を果たしています。例えば、2024年2月、スイスに本部を置く政府間機関である世界保健機関（WHO）は、2050年までに新たに発生するがん患者は3,500万人を超えると予測し、これは2022年に報告された推定2,000万人から77％増加することを示しています。このように、がん罹患率の増加はペグフィルグラスチムバイオシミラー市場の重要な促進要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ペグフィルグラスチムバイオシミラーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のペグフィルグラスチムバイオシミラー市場：成長率分析
• 世界のペグフィルグラスチムバイオシミラー市場の実績：規模と成長, 2019-2024
• 世界のペグフィルグラスチムバイオシミラー市場の予測：規模と成長, 2024-2029, 2034F
• 世界ペグフィルグラスチムバイオシミラー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のペグフィルグラスチムバイオシミラー市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法治療
• 移植
• その他の用途
• 世界のペグフィルグラスチムバイオシミラー市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• 通信販売薬局
• 世界のペグフィルグラスチムバイオシミラー市場、化学療法治療のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん患者に対する支持療法
• 化学療法誘発性好中球減少症の軽減
• 世界のペグフィルグラスチムバイオシミラー市場、移植のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 造血幹細胞移植
• 末梢血幹細胞移植
• 世界のペグフィルグラスチムバイオシミラー市場、その他のアプリケーションのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 慢性好中球減少症の治療
• 重症先天性好中球減少症の治療
• 腫瘍学におけるその他の支持療法

第7章 地域別・国別分析

• 世界のペグフィルグラスチムバイオシミラー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のペグフィルグラスチムバイオシミラー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ペグフィルグラスチムバイオシミラー市場：競合情勢
• ペグフィルグラスチムバイオシミラー市場：企業プロファイル
  • Amgen Overview, Products and Services, Strategy and Financial Analysis
  • Mylan N.V. Overview, Products and Services, Strategy and Financial Analysis
  • Sandoz（a Novartis division）Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Biocon Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Pfizer
• Celltrion Healthcare
• Coherus BioSciences
• Gedeon Richter
• Fresenius Kabi
• Hetero Labs
• Intas Pharmaceuticals
• LG Chem
• Merck KGaA
• Zydus Cadila
• Aurobindo Pharma
• Apotex Inc.
• Dr. Reddy's Laboratories
• Stada Arzneimittel AG
• Reddy's Laboratories

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ペグフィルグラスチムバイオシミラー市場2029：新たな機会を提供する国
• ペグフィルグラスチムバイオシミラー市場2029：新たな機会を提供するセグメント
• ペグフィルグラスチムバイオシミラー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Pegfilgrastim biosimilars are biosimilar products designed to be used in conjunction with supportive care for individuals with non-myeloid cancer. These biosimilars aid in preventing or treating infections resulting from myelosuppressive chemotherapy by stimulating the production of specific white blood cells.

The diverse applications of pegfilgrastim biosimilars include their use in chemotherapy treatment, transplantation, and other medical scenarios. Chemotherapy is a cancer treatment method that involves the administration of one or more anti-cancer medications following a specified protocol. These biosimilars are made available through various distribution channels, including hospital pharmacies, retail pharmacies, and mail-order pharmacies.

The pegfilgrastim biosimilars market research report is one of a series of new reports from The Business Research Company that provides pegfilgrastim biosimilars market statistics, including pegfilgrastim biosimilars industry global market size, regional shares, competitors with a pegfilgrastim biosimilars market share, detailed pegfilgrastim biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the pegfilgrastim biosimilars industry. This pegfilgrastim biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pegfilgrastim biosimilars market size has grown rapidly in recent years. It will grow from $1.56 billion in 2024 to $1.8 billion in 2025 at a compound annual growth rate (CAGR) of 15.3%. The growth in the historic period can be attributed to increase in cancer prevalence, government initiatives, increased healthcare expenditure, increase in biopharmaceutical R&D expenditure, low cost of biosimilars, and high penetration of the biosimilar drugs.

The pegfilgrastim biosimilars market size is expected to see rapid growth in the next few years. It will grow to $3.44 billion in 2029 at a compound annual growth rate (CAGR) of 17.5%. The growth in the forecast period can be attributed to increasing prevalence of cancer, aging population, increasing number of approvals, and targets and incentives. Major trends in the forecast period include taking advantage of the less stringent regulations to develop new and improved biosimilars, investing extensively in R&D activities for the development of effective and innovative biologics, focusing on establishing strategic partnerships with the large players to expand their research and developments activities in new drug developments and increasing their focus on M&A growth strategies to expand the customer base and their geographic markets, and increasing focus towards the production of biosimilars for neutropenia treatment to improve revenues and product offerings.

Government initiatives aimed at promoting the development of biosimilars are anticipated to be a driving force behind the pegfilgrastim biosimilars market. Governments on a global scale are prioritizing biosimilar development due to its cost-effectiveness. Initiatives such as the Biosimilar Action Plan launched by the US Food and Drug Administration (FDA) to expand treatment options and the commitment of the Australian government to the Biosimilar Awareness Initiative through a $5 million grant to support biosimilar education and activities highlight the concerted efforts to enhance awareness and production of biosimilars. These endeavors contribute to the overall growth of the pegfilgrastim biosimilars market.

The rising incidence of cancer is anticipated to drive the growth of the pegfilgrastim biosimilars market in the coming years. Cancer encompasses a range of diseases characterized by the uncontrolled proliferation and spread of abnormal cells. Pegfilgrastim biosimilars play a crucial role in mitigating the risk of infection among cancer patients undergoing chemotherapy by promoting white blood cell production. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, projected that by 2050, more than 35 million new cancer cases are expected, representing a 77% increase from the estimated 20 million cases reported in 2022. Thus, the increasing incidence of cancer is a key driver for the pegfilgrastim biosimilars market.

Companies operating in the pegfilgrastim biosimilar market are enhancing their product innovation through strategic collaborations. To thrive in the increasingly competitive market, these companies are not only developing innovative products but also leveraging partnerships to share skills and expertise. While collaborations with academic and research institutions have been a common practice, this trend has gained momentum in recent years. For example, in May 2023, Amneal Pharmaceuticals, a US-based generics and specialty pharmaceutical company, joined forces with Kashiv Biosciences, a US-based integrated biosciences company, to collaboratively develop and introduce Fylnetra (pegfilgrastim-pbbk), a biosimilar pegfilgrastim. Fylnetra is a preservative-free, clear solution provided in a 6 mg/0.6 mL single-dose prefilled syringe, aiming to reduce infection risks, specifically febrile neutropenia, in patients with non-myeloid cancers undergoing certain myelosuppressive anti-cancer treatments.

Major companies in the pegfilgrastim biosimilars market are introducing high-quality products such as Stimufend to offer improved alternatives. Stimufend, launched by Fresenius Kabi, a Germany-based healthcare company, in February 2023, is a therapeutic drug designed to assist cancer patients in addressing neutropenia. Available as a 6 mg/0.6 mL solution in a single-use pre-filled syringe with a built-in needle guard, Stimufend marks the company's entry into the U.S. biosimilars market for cancer care, providing healthcare professionals with a high-quality treatment alternative.

In February 2022, Biocon Biologics Ltd., an India-based fully integrated biopharmaceutical company, completed the acquisition of Viatris' biosimilar business for $3.34 billion. This strategic move enables Biocon Biologics to direct-market more of its existing and upcoming biosimilars. As part of the acquisition, Viatris, a US-based pharmaceutical and healthcare corporation, is expected to provide commercial and other transition services to ensure a smooth transition and maintain customer service for an anticipated two-year term.

Major companies operating in the pegfilgrastim biosimilars market include Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy's Laboratories, Stada Arzneimittel AG, Reddy's Laboratories, Shanghai Henlius Biotech, Alvotech, EirGenix, Bharat Biotech, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm

North America was the largest region in the pegfilgrastim biosimilars market in 2024. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the pegfilgrastim biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The pegfilgrastim biosimilars market consists of sales of fulphila, pelgraz, pelmeg, udenyca, ziextenzo, grasustek, fylnetra, and stimufend. Values in this market are 'factory gate values,' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pegfilgrastim Biosimilars Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pegfilgrastim biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pegfilgrastim biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pegfilgrastim biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Application: Chemotherapy Treatment, Transplantation, Other Applications
• 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies
• Subsegments:
• 1) By Chemotherapy Treatment: Supportive Care for Cancer Patients; Reduction of Chemotherapy-Induced Neutropenia
• 2) By Transplantation: Hematopoietic Stem Cell Transplantation; Peripheral Blood Stem Cell Transplantation
• 3) By Other Applications: Treatment of Chronic Neutropenia; Treatment of Severe Congenital Neutropenia; Other Supportive Therapies in Oncology
• Companies Mentioned: Amgen; Mylan N.V.; Sandoz (a Novartis division); Teva Pharmaceutical Industries Ltd.; Biocon
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pegfilgrastim Biosimilars Market Characteristics

3. Pegfilgrastim Biosimilars Market Trends And Strategies

4. Pegfilgrastim Biosimilars Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Pegfilgrastim Biosimilars Growth Analysis And Strategic Analysis Framework

• 5.1. Global Pegfilgrastim Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Pegfilgrastim Biosimilars Market Growth Rate Analysis
• 5.4. Global Pegfilgrastim Biosimilars Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Pegfilgrastim Biosimilars Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Pegfilgrastim Biosimilars Total Addressable Market (TAM)

6. Pegfilgrastim Biosimilars Market Segmentation

• 6.1. Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy Treatment
• Transplantation
• Other Applications
• 6.2. Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Mail-Order Pharmacies
• 6.3. Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Chemotherapy Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Supportive Care for Cancer Patients
• Reduction of Chemotherapy-Induced Neutropenia
• 6.4. Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hematopoietic Stem Cell Transplantation
• Peripheral Blood Stem Cell Transplantation
• 6.5. Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Other Applications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Treatment of Chronic Neutropenia
• Treatment of Severe Congenital Neutropenia
• Other Supportive Therapies in Oncology

7. Pegfilgrastim Biosimilars Market Regional And Country Analysis

• 7.1. Global Pegfilgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Pegfilgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pegfilgrastim Biosimilars Market

• 8.1. Asia-Pacific Pegfilgrastim Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pegfilgrastim Biosimilars Market

• 9.1. China Pegfilgrastim Biosimilars Market Overview
• 9.2. China Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pegfilgrastim Biosimilars Market

• 10.1. India Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pegfilgrastim Biosimilars Market

• 11.1. Japan Pegfilgrastim Biosimilars Market Overview
• 11.2. Japan Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pegfilgrastim Biosimilars Market

• 12.1. Australia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pegfilgrastim Biosimilars Market

• 13.1. Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pegfilgrastim Biosimilars Market

• 14.1. South Korea Pegfilgrastim Biosimilars Market Overview
• 14.2. South Korea Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pegfilgrastim Biosimilars Market

• 15.1. Western Europe Pegfilgrastim Biosimilars Market Overview
• 15.2. Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pegfilgrastim Biosimilars Market

• 16.1. UK Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pegfilgrastim Biosimilars Market

• 17.1. Germany Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pegfilgrastim Biosimilars Market

• 18.1. France Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pegfilgrastim Biosimilars Market

• 19.1. Italy Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pegfilgrastim Biosimilars Market

• 20.1. Spain Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pegfilgrastim Biosimilars Market

• 21.1. Eastern Europe Pegfilgrastim Biosimilars Market Overview
• 21.2. Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pegfilgrastim Biosimilars Market

• 22.1. Russia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pegfilgrastim Biosimilars Market

• 23.1. North America Pegfilgrastim Biosimilars Market Overview
• 23.2. North America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pegfilgrastim Biosimilars Market

• 24.1. USA Pegfilgrastim Biosimilars Market Overview
• 24.2. USA Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pegfilgrastim Biosimilars Market

• 25.1. Canada Pegfilgrastim Biosimilars Market Overview
• 25.2. Canada Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pegfilgrastim Biosimilars Market

• 26.1. South America Pegfilgrastim Biosimilars Market Overview
• 26.2. South America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pegfilgrastim Biosimilars Market

• 27.1. Brazil Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pegfilgrastim Biosimilars Market

• 28.1. Middle East Pegfilgrastim Biosimilars Market Overview
• 28.2. Middle East Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pegfilgrastim Biosimilars Market

• 29.1. Africa Pegfilgrastim Biosimilars Market Overview
• 29.2. Africa Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pegfilgrastim Biosimilars Market Competitive Landscape And Company Profiles

• 30.1. Pegfilgrastim Biosimilars Market Competitive Landscape
• 30.2. Pegfilgrastim Biosimilars Market Company Profiles
  • 30.2.1. Amgen Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Mylan N.V. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sandoz (a Novartis division) Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Biocon Overview, Products and Services, Strategy and Financial Analysis

31. Pegfilgrastim Biosimilars Market Other Major And Innovative Companies

• 31.1. Pfizer
• 31.2. Celltrion Healthcare
• 31.3. Coherus BioSciences
• 31.4. Gedeon Richter
• 31.5. Fresenius Kabi
• 31.6. Hetero Labs
• 31.7. Intas Pharmaceuticals
• 31.8. LG Chem
• 31.9. Merck KGaA
• 31.10. Zydus Cadila
• 31.11. Aurobindo Pharma
• 31.12. Apotex Inc.
• 31.13. Dr. Reddy's Laboratories
• 31.14. Stada Arzneimittel AG
• 31.15. Reddy's Laboratories

32. Global Pegfilgrastim Biosimilars Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pegfilgrastim Biosimilars Market

34. Recent Developments In The Pegfilgrastim Biosimilars Market

35. Pegfilgrastim Biosimilars Market High Potential Countries, Segments and Strategies

• 35.1 Pegfilgrastim Biosimilars Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Pegfilgrastim Biosimilars Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Pegfilgrastim Biosimilars Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer